CEO Innovation Policy Update 11.19.26

With Democrats set to take control of Congress in January, the lame-duck session is increasingly defined by what Republicans can finish and what will carry into the new year.

At a glance

  • FDA commissioner: The White House withdrew Heidi Overton’s nomination a day before her HELP Committee vote. Confirming a permanent commissioner will likely fall to the incoming Democratic majority unless Republicans move fast on a replacement such as Sen. Roger Marshall. Kyle Diamantas stays on as acting commissioner.
  • OMB grant rule (block expires Dec. 11): None of the Senate’s 12 FY27 spending bills extends the block on OMB’s grant overhaul, which MassBio opposes. Leaders in both parties support carrying the block forward in the next stopgap. MassBio will keep engaging.
  • Drug pricing and patents: Senate Judiciary members from both parties criticized PBMs…
    Click here to view original post

    Click Here to Publish/Feature Your Company or Product News with Biotech Networks